课题基金 / 基金详情

Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and

Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and
硬皮病肺部并发症的生物标志物:SSc-PAH 和
批准号:
8380643
负责人:
HARRISON W FARBER
金额:
$32.02万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

HARRISON W FARBER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Pulmonary hypertension (PH) occurs in 10-50% of scleroderma (SSc) patients depending on the study and mode of diagnosis. PH increases with disease duration, with later age of disease onset, and is greater in males and in patients with limited SSc. PH is a leading cause of mortality in SSc patients; incidence may be increasing due to longer life span of SSc patients. Unlike PH resulting from hypoxemia due to interstitial lung disease (ILD), PH associated predominantly with limited SSc (IsSSc) is histologically identical to other forms of pulmonary arterial hypertension (PAH). Whether SSc-PAH has similar predispositions to other forms of PAH and/or whether the molecular basis is similar is not known. In contrast to other forms of PAH, with possible exception of HIV-associated PAH, SSc-PAH is characterized by autoimmunity. We have developed data demonstrating that a molecular profile reflecting immune processes exists in patients with SSC-PAH. TO investigate further the hypotheses that: 1) vascular changes in SSc-PAH result from EC dysfunction, initiated by interaction of autoimmunity and injury leading to subsequent excessive angiogenesis; and 2) specific markers of autoimmunity and EC injury and/or angiogenesis can define phenotypes in the SSc population and predict development and progression of PAH, we propose to: 1) Identify markers of inflammation/injury and angiogenesis in SSc patients with PAH (SSc-PAH phenotype) in patients with established SSc-PAH and in SSc patients who develop PAH during the tenure of this proposal. 2) Compare markers identified in patients with SSc-PAH with those markers identified in patients with SSc-ILD. Overlap Aim with Dr. Lafyatis. We will compare and contrast candidate molecules of the "SSc-PAH phenotype" with those of the "SSc-ILD phenotype", the two phenotypes most associated with morbidity and mortality in SSc. 3) Determine the relationship between outcomes in patients with SSc-PAH and vascular endothelial endoplasmic reticulum (ER) stress. Overlap Aim with Dr. Trojanowska. The proposed studies will determine a predictive phenotype important in development and outcome of PAH in SSc patients. This may allow better screening, identify atrisk patients and, potentially, contribute to prevention strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome
  • 批准号:
    6900239
  • 项目类别:
  • 资助金额:
    $14.85万
  • 财政年份:
    2004
  • 负责人:
    HARRISON W FARBER
  • 依托单位:
Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens
  • 批准号:
    6904591
  • 项目类别:
  • 资助金额:
    $40.38万
  • 财政年份:
    2003
  • 负责人:
    HARRISON W FARBER
  • 依托单位:
Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens
  • 批准号:
    6769471
  • 项目类别:
  • 资助金额:
    $40.38万
  • 财政年份:
    2003
  • 负责人:
    HARRISON W FARBER
  • 依托单位:
Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens
  • 批准号:
    7091401
  • 项目类别:
  • 资助金额:
    $39.43万
  • 财政年份:
    2003
  • 负责人:
    HARRISON W FARBER
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: